Free Trial
NASDAQ:COLL

Collegium Pharmaceutical (COLL) Stock Price, News & Analysis

Collegium Pharmaceutical logo
$27.06 +0.06 (+0.22%)
Closing price 05/1/2025 04:00 PM Eastern
Extended Trading
$25.11 -1.95 (-7.20%)
As of 05/1/2025 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Collegium Pharmaceutical Stock (NASDAQ:COLL)

Key Stats

Today's Range
$26.16
$27.10
50-Day Range
$24.67
$30.56
52-Week Range
$23.23
$42.29
Volume
310,177 shs
Average Volume
442,325 shs
Market Capitalization
$869.49 million
P/E Ratio
11.66
Dividend Yield
N/A
Price Target
$43.60
Consensus Rating
Moderate Buy

Company Overview

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Collegium Pharmaceutical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

COLL MarketRank™: 

Collegium Pharmaceutical scored higher than 81% of companies evaluated by MarketBeat, and ranked 168th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Collegium Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Collegium Pharmaceutical has only been the subject of 3 research reports in the past 90 days.

  • Read more about Collegium Pharmaceutical's stock forecast and price target.
  • Earnings Growth

    Earnings for Collegium Pharmaceutical are expected to grow by 7.12% in the coming year, from $5.62 to $6.02 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Collegium Pharmaceutical is 11.66, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.76.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Collegium Pharmaceutical is 11.66, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.51.

  • Price to Book Value per Share Ratio

    Collegium Pharmaceutical has a P/B Ratio of 4.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Collegium Pharmaceutical's valuation and earnings.
  • Percentage of Shares Shorted

    14.46% of the float of Collegium Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    Collegium Pharmaceutical has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Collegium Pharmaceutical has recently decreased by 1.32%, indicating that investor sentiment is improving.
  • Dividend Yield

    Collegium Pharmaceutical does not currently pay a dividend.

  • Dividend Growth

    Collegium Pharmaceutical does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.46% of the float of Collegium Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    Collegium Pharmaceutical has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Collegium Pharmaceutical has recently decreased by 1.32%, indicating that investor sentiment is improving.
  • News Sentiment

    Collegium Pharmaceutical has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Collegium Pharmaceutical this week, compared to 5 articles on an average week.
  • Search Interest

    Only 1 people have searched for COLL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Collegium Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,334,994.00 in company stock.

  • Percentage Held by Insiders

    Only 2.51% of the stock of Collegium Pharmaceutical is held by insiders.

  • Read more about Collegium Pharmaceutical's insider trading history.
Receive COLL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

COLL Stock News Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
7COLL : What Analysts Are Saying...
See More Headlines

COLL Stock Analysis - Frequently Asked Questions

Collegium Pharmaceutical's stock was trading at $28.65 at the beginning of 2025. Since then, COLL shares have decreased by 5.5% and is now trading at $27.06.
View the best growth stocks for 2025 here
.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) issued its earnings results on Thursday, February, 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping analysts' consensus estimates of $1.54 by $0.09. The specialty pharmaceutical company had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a trailing twelve-month return on equity of 104.67%.
Read the conference call transcript
.

Collegium Pharmaceutical (COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Collegium Pharmaceutical's top institutional shareholders include Principal Financial Group Inc. (4.90%), Emerald Advisers LLC (2.57%), Emerald Mutual Fund Advisers Trust (1.79%) and Bank of New York Mellon Corp (0.75%). Insiders that own company stock include Joseph Ciaffoni, Colleen Tupper, Scott Dreyer, Shirley R Kuhlmann, Thomas B Smith, Garen G Bohlin and Michael Thomas Heffernan.
View institutional ownership trends
.

Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Collegium Pharmaceutical investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Arista Networks (ANET), Netflix (NFLX) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
2/27/2025
Today
5/01/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:COLL
Fax
N/A
Employees
210
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$43.60
High Stock Price Target
$50.00
Low Stock Price Target
$36.00
Potential Upside/Downside
+61.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
11.64
Forward P/E Ratio
4.80
P/E Growth
N/A
Net Income
$48.15 million
Pretax Margin
21.36%

Debt

Sales & Book Value

Annual Sales
$631.45 million
Cash Flow
$9.77 per share
Price / Cash Flow
2.76
Book Value
$5.99 per share
Price / Book
4.50

Miscellaneous

Free Float
30,966,000
Market Cap
$866.47 million
Optionable
Optionable
Beta
0.76

Social Links

10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:COLL) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners